ATE155813T1 - Her2 extrazellulare domäne - Google Patents

Her2 extrazellulare domäne

Info

Publication number
ATE155813T1
ATE155813T1 AT90908809T AT90908809T ATE155813T1 AT E155813 T1 ATE155813 T1 AT E155813T1 AT 90908809 T AT90908809 T AT 90908809T AT 90908809 T AT90908809 T AT 90908809T AT E155813 T1 ATE155813 T1 AT E155813T1
Authority
AT
Austria
Prior art keywords
extracellular domain
her2 extracellular
patient
her2 receptor
human
Prior art date
Application number
AT90908809T
Other languages
English (en)
Inventor
Robert Michael Hudziak
H Michael Shepard
Axel Ullrich
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23392786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE155813(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE155813T1 publication Critical patent/ATE155813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AT90908809T 1989-05-19 1990-05-18 Her2 extrazellulare domäne ATE155813T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35431989A 1989-05-19 1989-05-19

Publications (1)

Publication Number Publication Date
ATE155813T1 true ATE155813T1 (de) 1997-08-15

Family

ID=23392786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90908809T ATE155813T1 (de) 1989-05-19 1990-05-18 Her2 extrazellulare domäne

Country Status (8)

Country Link
US (2) US6015567A (de)
EP (1) EP0474727B1 (de)
AT (1) ATE155813T1 (de)
CA (1) CA2055441C (de)
DE (1) DE69031120T2 (de)
DK (1) DK0474727T3 (de)
ES (1) ES2106033T3 (de)
WO (1) WO1990014357A1 (de)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861511B1 (en) * 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US7282345B1 (en) * 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
JP3859695B2 (ja) * 1989-08-04 2006-12-20 バーレックス ラボラトリーズ インコーポレイテッド Ｃ―ｅｒｂＢ―２外部ドメイン：ＧＰ７５
DE69108716T2 (de) * 1990-01-26 1995-08-17 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
CA2037440A1 (en) * 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7285531B1 (en) 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7094749B1 (en) 1991-04-10 2006-08-22 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
DE4129533A1 (de) * 1991-09-05 1993-03-11 Max Planck Gesellschaft Mutierter wachstumsfaktorrezeptor als arzneimittel und seine verwendung zur behandlung von krebs
CA2117303C (en) * 1991-11-29 2000-10-17 Sunil Chada Anti-cancer immunotherapeutic vector constructs
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
IT1276662B1 (it) * 1995-04-04 1997-11-03 Uni Degli Studi Camerino Vaccini polinucleotidici
US6465623B2 (en) 1995-05-02 2002-10-15 Garvan Institute Of Medical Research GDU, a novel signalling protein
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
WO1998009650A1 (fr) 1996-09-06 1998-03-12 Mitsubishi Chemical Corporation Preparations vaccinales
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
AU747577B2 (en) * 1997-01-30 2002-05-16 Novartis Vaccines And Diagnostics, Inc. Use of microparticles with adsorbed antigen to stimulate immune responses
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) * 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
NZ513062A (en) * 1999-01-29 2003-10-31 Smithkline Beecham HER-2/neu fusion proteins
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
KR100797308B1 (ko) 1999-06-25 2008-01-23 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
DK1189634T3 (da) * 1999-06-25 2007-06-25 Genentech Inc Behandling af prostatacancer med anti-ErbB2-antistoffer
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
AU6620300A (en) 1999-08-03 2001-02-19 Ohio State University, The Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
ES2330301T3 (es) 1999-08-27 2009-12-09 Genentech, Inc. Dosificaciones para tratamiento con anticuerpos anti-erbb2.
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US20020039583A1 (en) * 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
AU3458401A (en) 2000-01-25 2001-08-07 Genentech Inc. Compositions and methods for treatment of cancer
AU2001241710B2 (en) * 2000-02-25 2005-07-21 The Regents Of The University Of California Membrane estrogen receptor-directed therapy in breast cancer
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (de) * 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
NZ522444A (en) 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
ES2394293T3 (es) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7638598B2 (en) 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
AU2002303330B2 (en) 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
AU2002365258A1 (en) 2001-10-12 2003-09-02 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
CA2490542C (en) 2002-05-23 2013-07-16 Mark I. Greene Fas peptide mimetics and uses thereof
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
KR101106441B1 (ko) * 2003-03-19 2012-01-18 바이오겐 아이덱 엠에이 인코포레이티드 노고 수용체 결합 단백질
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
EP1745073A2 (de) * 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
EP1765313A2 (de) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Verbindungen als immunstimulatoren
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
CA2583230A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
JP2008530123A (ja) * 2005-02-09 2008-08-07 ジェネンテック・インコーポレーテッド マトリックスメタロプロテアーゼアンタゴニストを用いたｈｅｒ２のシェディングの阻害
EP2399605A1 (de) * 2005-02-23 2011-12-28 Genentech, Inc. Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7691396B2 (en) 2005-06-15 2010-04-06 The Ohio State University Research Foundation Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes
JP2009502123A (ja) 2005-07-08 2009-01-29 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５抗体およびその使用
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101355960A (zh) 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
CA2646539A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US20100010217A1 (en) * 2006-03-23 2010-01-14 Valiante Nicholas M Methods for the preparation of imidazole-containing compounds
EP3284478A1 (de) * 2006-08-15 2018-02-21 The Trustees of the University of Pennsylvania Zusammensetzungen mit hmw-maa und fragmenten davon zur behandlung von krebs
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2084267B1 (de) * 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Krebsstammzellen-antigen-impfstoffe und entsprechende verfahren
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
PL2162149T3 (pl) 2007-06-01 2014-04-30 Henry M Jackson Found Advancement Military Medicine Inc Szczepionka do zapobiegania nawrotowi raka sutka
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
EP2170384B1 (de) 2007-07-02 2016-04-13 Etubics Corporation Verfahren und zusammensetzungen zur herstellung eines adenovirus-vektors zur verwendung mit multiplen impfungen
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
WO2010028066A2 (en) * 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
DK2403935T3 (en) 2009-03-04 2017-09-11 Univ Pennsylvania COMPOSITIONS CONTAINING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
DK2536748T3 (da) 2010-02-18 2014-10-13 Genentech Inc Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
EP2576613A1 (de) 2010-06-07 2013-04-10 Pfizer Inc. Her-2-peptide und impfstoffe
CN103282048B (zh) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN103687611A (zh) 2011-03-11 2014-03-26 阿德瓦希斯公司 基于李斯特菌属的佐剂
WO2013025853A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Neuregulin antibodies and uses thereof
US10258676B2 (en) 2011-09-06 2019-04-16 Agency For Science, Technology And Research Polypeptide vaccine
PL2766040T3 (pl) 2011-10-14 2019-11-29 Hoffmann La Roche Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CN104271761B (zh) 2011-11-30 2017-03-15 霍夫曼-拉罗奇有限公司 癌症中的erbb3突变
EP2788500A1 (de) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identifizierung von non-respondern auf her2-inhibitoren
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
EP2777711A1 (de) * 2013-03-11 2014-09-17 Icon Genetics GmbH HER2/neu-Krebsimpfstoff
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
AU2015229583B2 (en) 2014-03-11 2020-07-09 Molecular Templates, Inc. Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
EP3116905B1 (de) 2014-03-11 2019-01-30 Molecular Templates, Inc. Proteine mit bindungsregionen, shiga-toxin-a-untereinheiteneffektorregionen und carboxyterminierten, endoplasmatischen retikulumlokalisierungssignalmotiven
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3302551A2 (de) 2015-05-30 2018-04-11 H. Hoffnabb-La Roche Ag Verfahren zur behandlung von her2-positivem, lokal fortgeschrittenem oder vorher unbehandeltem metastatischem brustkrebs
US20180258143A1 (en) 2015-05-30 2018-09-13 Molecular Templates, Inc. De-Immunized, Shiga Toxin A Subunit Scaffolds and Cell-Targeting Molecules Comprising the Same
EP3325510A2 (de) 2015-07-26 2018-05-30 Molecular Templates, Inc. Gegen zellen gerichtete moleküle mit effektoren der shigatoxin-a-untereinheit und cd8+-t-zellepitopen
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
TW201818940A (zh) 2016-11-04 2018-06-01 美商建南德克公司 Her2陽性乳癌之治療
MX2019007801A (es) 2016-12-28 2019-10-30 Genentech Inc Tratamiento de cáncer avanzado con expresión de her2.
EP3570884B1 (de) 2017-01-17 2020-09-30 Genentech, Inc. Subkutane her2-antikörperformulierungen
JP7082424B2 (ja) 2017-01-25 2022-06-08 モレキュラー テンプレーツ，インク． 脱免疫化された志賀毒素ａサブユニットエフェクター及びｃｄ８＋ｔ細胞エピトープを含む細胞標的化分子
CN117180422A (zh) 2017-03-02 2023-12-08 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3615695A1 (de) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2-mutationen in der transmembran- oder juxtamembran-domäne
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US4761371A (en) * 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5126433A (en) 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA1341191C (en) * 1988-04-18 2001-02-27 Robert Allan Weinberg Detection of neu gene expression and products
JP3859695B2 (ja) * 1989-08-04 2006-12-20 バーレックス ラボラトリーズ インコーポレイテッド Ｃ―ｅｒｂＢ―２外部ドメイン：ＧＰ７５
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor

Also Published As

Publication number Publication date
EP0474727B1 (de) 1997-07-23
EP0474727A1 (de) 1992-03-18
DK0474727T3 (da) 1998-01-12
US6015567A (en) 2000-01-18
DE69031120T2 (de) 1998-01-15
ES2106033T3 (es) 1997-11-01
EP0474727A4 (en) 1992-08-26
CA2055441C (en) 2003-01-07
US6333169B1 (en) 2001-12-25
WO1990014357A1 (en) 1990-11-29
CA2055441A1 (en) 1990-11-20
DE69031120D1 (de) 1997-09-04

Similar Documents

Publication Publication Date Title
DK0474727T3 (da) HER2 ekstracellulært domæne
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
NL300156I1 (nl) Therapeutische toepassing van chimere en radioactief gemerkte antilichamen tegen humane B-Lymfocyt beperkt differentiatie antigeen voor de behandelingvan B-Cel lymfoom.
GB9002957D0 (en) Probe,and method of use thereof for biomodulation of tissue,nerve and immune systems
DK0585943T3 (da) Opløselige ligander for CD40
ZA90171B (en) Treatment methods and vaccines for stimulating an immune response
NO890089D0 (no) Fremgangsmaater for stimulering av haarvekst.
LTIP702A (en) A slimming pharmaceutical composition
IT8622795A0 (it) Metodo per un efficace trattamento idratante della pelle, particolarmente per applicazione in campo cosmetico.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
IT1198233B (it) Metodo per la determinazione di anticorpi antisporozoita di p. falciparum nel sangue umano
DE3373978D1 (en) Composition for the care or treatment of the human skin
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
IT1208373B (it) Poltrona per trattamenti odontoiatrici
FR2668152B1 (fr) Derives n,o spirocycliques de cyclotriphosphazenes, leur preparation et leur application en therapeutique.
IT8809313A0 (it) Macchina per il trattamento terapeutico di lombalgie e lombosciatalgie
FR2666582B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique.
SE9101341D0 (sv) New medicinal use
SE9401919L (sv) Implanterbar anordning
GR3021983T3 (en) Cross-reactive influenza a immunization
FR2529076B1 (fr) Dispositif pour le traitement therapeutique et stimulateur, combine, des gencives
FR2637595B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
IT8467865A0 (it) Procedimento e dispositivo per il trattamento di prodotti agricoli raccolti meccanicamente e macchina comprendente il suddetto dispositivo
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee